Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sciclone Pharmaceuticals Inc reaffirms FY 2014 revenue guidance; issues FY 2014 EPS guidance below analysts' estimates


Wednesday, 12 Mar 2014 06:00am EDT 

Sciclone Pharmaceuticals Inc:Expects FY 2014 revenue to be in the range of $130 and $135 mln.Expects non-GAAP EPS to be in the range between $0.41 and $0.47.FY 2014 revenue of $133 mln and EPS of $0.52 - Thomson Reuters I/B/E/S. 

Company Quote

6.34
-0.01 -0.16%
4:00pm EDT